Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Trinity Cancer Care Center
mi
from
Minot, ND
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Trinity Cancer Care Center
mi
from
Minot, ND
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Akron General Medical Center
mi
from
Akron, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Akron City Hospital
mi
from
Akron, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Cancer Center at Christ Hospital
mi
from
Cincinnati, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Cancer Center at Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Ireland Cancer Center
mi
from
Cleveland, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Columbus
mi
from
Columbus, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Columbus
mi
from
Columbus, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Dayton
mi
from
Dayton, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Parma Community General Hospital
mi
from
Parma, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Parma Community General Hospital
mi
from
Parma, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Frank C. Love Cancer Institute at St. Anthony Hospital
mi
from
Oklahoma City, OK
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Frank C. Love Cancer Institute at St. Anthony Hospital
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Oklahoma University Medical Center at University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Oklahoma University Medical Center at University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
St. John Health System
mi
from
Tulsa, OK
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
St. John Health System
mi
from
Tulsa, OK
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Oklahoma
mi
from
Tulsa, OK
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Oklahoma
mi
from
Tulsa, OK
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Abington Memorial Hospital
mi
from
Abington, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
mi
from
Allentown, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Geisinger Medical Center
mi
from
Danville, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Pocono Cancer Center
mi
from
East Stroudsburg, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Pocono Cancer Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Abramson Cancer Center of the University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Abramson Cancer Center of the University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Veterans Affairs Medical Center - Philadelphia
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Veterans Affairs Medical Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Reading Hospital and Medical Center
mi
from
Reading, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Wilkes Barre General Hospital
mi
from
Wilkes-Barre, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Wilkes Barre General Hospital
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Roger Williams Medical Center
mi
from
Providence, RI
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Greenville
mi
from
Greenville, SC
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
West Tennessee Cancer Center at Jackson-Madison County General Hospital
mi
from
Jackson, TN
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
West Tennessee Cancer Center at Jackson-Madison County General Hospital
mi
from
Jackson, TN
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Arlington Cancer Center
mi
from
Arlington, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Arlington Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials